# US 2008/0075762 A1 · Compositions for delivery of drug combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075762 A1
- Document ID: US20080075762A1
- Status: Published application
- Kind: A1
- Application number: 11/841,786
- Filed: 2007-08-20
- Published: 2008-03-27
- Earliest claimed: 2001-10-03
- Inventors: Paul Tardi; Troy Harasym; Murray Webb; Clifford Shew
- Web page: https://patentgrep.com/patent/US20080075762A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.

## Claims

### Claim 1

A composition which comprises delivery vehicles, said delivery vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio of the first agent to the second agent which exhibits a non-antagonistic biologic effect to relevant cells in culture or a cell-free system over at least 5% of such concentration range where >1% of the cells are affected (fa>0.01) in an in vitro assay for biologic effect.

### Claim 2

A composition which comprises delivery vehicles, said delivery vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio of the first agent to the second agent which exhibits a non-antagonistic cytotoxic or cytostatic or biologic effect to relevant cells wherein said agents are antineoplastic agents.

### Claim 3 (depends on 2)

The composition of claim 2 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range where >1% of relevant cells are affected (fa>0.01) in an in vitro assay for cytotoxicity.

### Claim 4 (depends on 1)

The composition of claim 1 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 10-90% of the cells are affected (fa>0.1-0.9) in said in vitro assay.

### Claim 5 (depends on 4)

The composition of claim 4 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 20-80% of the cells are affected (fa=0.2-0.8) in said in vitro assay.

### Claim 6 (depends on 5)

The composition of claim 5 wherein said non-antagonistic effect is exhibited over at least 20% of the concentration range such that 20-80% of the cells are affected in said in vitro assay.

### Claim 7 (depends on 1)

The composition of claim 1 which, when administered to a subject, provides a therapeutic activity greater than that which is obtained when said agents are administered in the same ratio but not stably associated with delivery vehicles.

### Claim 8 (depends on 1)

The composition of claim 1 wherein said agents are antineoplastic agents.

### Claim 9 (depends on 1)

The composition of claim 1 wherein the composition comprises a third agent.

### Claim 10 (depends on 1)

The composition of claim 1 wherein said delivery vehicles have a mean diameter of between 4.5 and 500 nm.

### Claim 11 (depends on 10)

The composition of claim 10 wherein said vehicles have a mean diameter of less than 250 nm.

### Claim 12 (depends on 1, 2)

The composition of claim 1 or 2 wherein said delivery vehicles comprise
liposomes, and/or
lipid micelles, and/or
block copolymer micelles, and/or
microparticles, and/or
nanoparticles, and/or
polymer lipid hybrid systems, and/or
derivatized single chain polymers.

### Claim 13 (depends on 1)

The composition of claim 1 wherein said first and second agents are co-encapsulated.

### Claim 14 (depends on 13)

The composition of claim 13 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 10-90% of the cells are affected (fa=0.1-0.9) in said in vitro assay.

### Claim 15 (depends on 14)

The composition of claim 14 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 20-80% of the cells are affected (fa=0.2-0.8) in said in vitro assay.

### Claim 16 (depends on 15)

The composition of claim 15 wherein said non-antagonistic effect is exhibited over at least 20% of the concentration range such that 20-80% of the cells are affected in said in vitro assay.

### Claim 17 (depends on 2)

The composition of claim 2 which, when administered to a subject, provides a therapeutic activity greater than that which is obtained when said agents are administered in the same ratio but not stably associated with delivery vehicles.

### Claim 18 (depends on 2)

The composition of claim 2 wherein at least one of the agents is selected from the group consisting of a DNA damaging agent, a DNA repair inhibitor, a topoisomerase I inhibitor, a topoisomerase II inhibitor, a cell checkpoint inhibitor, a CDK inhibitor, a receptor tyrosine kinase inhibitor, a cytotoxic agent, an apoptosis inducing agent, an antimetabolite, a cell cycle control inhibitor, a therapeutic lipid, a telomerase inhibitor, an anti-angiogenic agent, a mitochondrial poison, a signal transduction inhibitor and an immunoagent.

### Claim 19 (depends on 18)

The composition of claim 18 wherein the first agent is a cytotoxic agent and the second agent is a cell-cycle inhibitor, or
wherein the first agent is a DNA damaging agent and the second agent is a DNA repair inhibitor, or
wherein the first agent is a topoisomerase I inhibitor and the second agent is a S/G2− or a G2/M-checkpoint inhibitor, or
wherein the first agent is a G1/S checkpoint inhibitor or a cyclin-dependent kinase inhibitor and the second agent is a G2/M checkpoint inhibitor, or
wherein the first agent is a receptor kinase inhibitor and the second agent is a cytotoxic agent, or
wherein the first agent is an apoptosis-inducing agent and the second agent is a cytotoxic agent, or
wherein the first agent is an apoptosis-inducing agent and the second agent is a cell-cycle control agent, or
wherein the first agent is a telomerase inhibitor and the second agent is a cell-cycle control inhibitor, or
wherein the first and second agents are antimetabolites, or
wherein the first and second agents are cytotoxic agents, or
wherein the first agent is a therapeutic lipid and the second agent is a cytotoxic agent, or
wherein the first agent is a topoisomerase I inhibitor and the second agent is a DNA repair inhibitor, or
wherein the apoptosis-inducing agent is a serine-containing lipid.

### Claim 20 (depends on 2)

The composition of claim 2
wherein the first agent is irinotecan and the second agent is 5-FU or FUDR, or
wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR, or
wherein the first agent is idarubicin and the second agent is AraC or FUDR, or
wherein the first agent is oxaliplatin and the second agent is 5-FU or FUDR, or
wherein the first agent is irinotecan and the second agent is cisplatin (or carboplatin), or
wherein the first agent is gemcitabine and the second agent is cisplatin (or carboplatin), or
wherein the first agent is methotrexate and the second agent is 5-FU or FUDR, or
wherein the first agent is paclitaxel and the second agent is cisplatin (or carboplatin), or
wherein the first agent is etoposide and the second agent is cisplatin (or carboplatin), or
wherein the first agent is docetaxel or paclitaxel and the second agent is doxorubicin, or
wherein the first agent is doxorubicin and the second agent is vinorelbine, or
wherein the first agent is carboplatin and the second agent is vinorelbine, or
wherein the first agent is 5-FU or FUDR and the second agent is gemcitabine.

### Claim 21

A method to prepare a composition comprising delivery vehicles, said vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio which is non-antagonistic, which method comprises
a) determining in a relevant cell culture assay or cell-free assay for biological activity a mole ratio of said first and second agent which is non-antagonistic over at least 5% of the concentration range over which greater than 1% of cells are affected (f, >0.01) by said ratio of agents, and
b) encapsulating with said delivery vehicles a mole ratio of agents determined to be non-antagonistic in step a).

### Claim 22

A method to prepare a composition comprising drug delivery vehicles, said vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio which is non-antagonistic, which method comprises
a) determining in a relevant cell culture assay or cell-free assay a mole ratio of said first and second agent which is non-antagonistic, wherein said agents are antineoplastic agents and
b) encapsulating with said delivery vehicles a mole ratio of agents determined to be non-antagonistic in step a).

### Claim 23 (depends on 21)

The method of claim 21 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 1%-99% of the cells are affected (fa=0.01-0.99) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 24 (depends on 23)

The method of claim 23 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 10-90% of the cells are affected (fa=0.1-0.9) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 25 (depends on 24)

The method of claim 24 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 20-80% of the cells are affected (fa=0.2-0.8) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 26 (depends on 25)

The method of claim 25 wherein said synergistic effect is exhibited over at least 20% of the concentration range such that 20-80% of the cells are affected in an in vitro assay for cytotoxicity or cytostasis.

### Claim 27 (depends on 22)

The method of claim 22 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that>1% of the cells are affected (fa>0.01) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 28 (depends on 27)

The method of claim 27 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 10-90% of the cells are affected (fa=0.1-0.9) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 29 (depends on 28)

The method of claim 28 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 20-80% of the cells are affected (fa=0.2-0.8) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 30 (depends on 29)

The method of claim 29 wherein said synergistic effect is exhibited over at least 20% of the concentration range such that 20-80% of the cells are affected in an in vitro assay for cytotoxicity or cytostasis.

### Claim 31 (depends on 21)

The method of claim 21, wherein said determining employs testing at least one ratio of said agents at a multiplicity of concentrations and applying an algorithm to calculate a synergistic, additive, or antagonistic effect for said ratio over a range of concentrations.

### Claim 32 (depends on 31)

The method of claim 31 which employs testing a multiplicity of ratios.

### Claim 33 (depends on 31)

The method of claim 31 wherein said algorithm is the Chou-Talalay median effect method.

### Claim 34 (depends on 31)

The method of claim 31 wherein said agents are antineoplastic agents.

### Claim 35 (depends on 22)

The method of claim 22 wherein at least one of the agents is selected from the group consisting of a DNA damaging agent, a DNA repair inhibitor, a topoisomerase I inhibitor, a topoisomerase II inhibitor, a checkpoint inhibitor, a CDK inhibitor, a receptor tyrosine kinase inhibitor, a cytotoxic agent, an apoptosis inducing agent, an antimetabolite, a cell cycle control inhibitor, a therapeutic lipid, a telomerase inhibitor, an anti-angiogenic agent, a mitochondrial poison, a signal transduction inhibitor and an immunoagent.

### Claim 36 (depends on 22)

The method of claim 22 wherein the first agent is a cytotoxic agent and the second agent is a cell-cycle inhibitor, or
wherein the first agent is a DNA damaging agent and the second agent is a DNA repair inhibitor, or
wherein the first agent is a topoisomerase I inhibitor and the second agent is a S/G2− or a G2/M-checkpoint inhibitor, or
wherein the first agent is a G1/S checkpoint inhibitor or a cyclin-dependent kinase inhibitor and the second agent is a G2/M checkpoint inhibitor, or
wherein the first agent is a receptor kinase inhibitor and the second agent is a cytotoxic agent, or
wherein the first agent is an apoptosis-inducing agent and the second agent is a cytotoxic agent, or
wherein the first agent is an apoptosis-inducing agent and the second agent is a cell-cycle control agent, or
wherein the first agent is a telomerase inhibitor and the second agent is a cell-cycle control inhibitor, or
or wherein the first and second agents are antimetabolites, or
wherein the first and second agents are cytotoxic agents, or
wherein the first agent is a therapeutic lipid and the second agent is a cytotoxic agent, or
wherein the first agent is a topoisomerase I inhibitor and the second agent is a DNA repair inhibitor, or
wherein the apoptosis-inducing agent is a serine-containing lipid.

### Claim 37 (depends on 27)

The method of claim 27
wherein the first agent is irinotecan and the second agent is 5-FU or FUDR, or
wherein the first agent is cisplatin and the second agent is 5-FU or FUDR, or
wherein the first agent is idarubicin and the second agent is AraC, or
wherein the first agent is oxaliplatin and the second agent is 5-FU or FUDR, or
wherein the first agent is irinotecan and the second agent is cisplatin (or carboplatin), or
wherein the first agent is gemcitabine and the second agent is cisplatin (or carboplatin), or
wherein the first agent is methotrexate and the second agent is 5-FU or FUDR, or
wherein the first agent is paclitaxel and the second agent is cisplatin (or carboplatin), or
wherein the first agent is etoposide and the second agent is cisplatin (or carboplatin), or
wherein the first agent is docetaxel or paclitaxel and the second agent is doxorubicin, or
wherein the first agent is adriamycin and the second agent is vinorelbine, or
wherein the first agent is carboplatin and the second agent is vinorelbine, or
wherein the first agent is 5-FU or FUDR and the second agent is gemcitabine.

### Claim 38 (depends on 21)

A composition prepared by the method of claim 21.

### Claim 39 (depends on 22)

A composition prepared by the method of claim 22.

### Claim 40 (depends on 31)

A composition prepared by the method of claim 31.

### Claim 41 (depends on 1)

A method to treat a disease condition in a subject which method comprises administering to a subject in need of such treatment a therapeutically effective amount of the composition of claim 1.

### Claim 42 (depends on 2)

A method to treat a disease condition in a subject which method comprises administering to a subject in need of such treatment a therapeutically effective amount of the composition of claim 2.

### Claim 43 (depends on 38)

A method to treat a disease condition in a subject which method comprises administering to a subject in need of such treatment a therapeutically effective amount of the composition of claim 38.

### Claim 44 (depends on 39)

A method to treat a disease condition in a subject which method comprises administering to a subject in need of such treatment a therapeutically effective amount of the composition of claim 39.

### Claim 45 (depends on 41)

The method of claim 41 wherein the subject is a human.

### Claim 46 (depends on 41)

The method of claim 41 wherein the subject is a non-human mammal or avian.

### Claim 47 (depends on 42)

The method of claim 42 wherein the subject is a human.

### Claim 48 (depends on 42)

The method of claim 42 wherein the subject is a non-human mammal or avian.

### Claim 49

A method to treat a disease condition in a subject which method comprises administering to a subject in need of such treatment a therapeutically effective amount of a first composition comprising delivery vehicles stably associated with at least a first therapeutic agent and a second composition comprising delivery vehicles stably associated with at least a second therapeutic agent,
wherein the delivery vehicles in said first and second composition are coordinated with respect to pharmacokinetics; and
wherein said administering is at a ratio of first therapeutic agent to second therapeutic agent that is non-antagonistic.

### Claim 50 (depends on 49)

The method of claim 49 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 1%-99% of the cells are affected (fa=0.01-0.99) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 51 (depends on 50)

The method of claim 50 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 10-90% of the cells are affected (fa=0.1-0.9) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 52 (depends on 51)

The method of claim 51 wherein said non-antagonistic effect is exhibited over at least 5% of the concentration range such that 20-80% of the cells are affected (fa=0.2-0.8) in an in vitro assay for cytotoxicity or cytostasis.

### Claim 53 (depends on 52)

The method of claim 52 wherein said synergistic effect is exhibited over at least 20% of the concentration range such that 20-80% of the cells are affected in an in vitro assay for cytotoxicity or cytostasis.

### Claim 54

A kit for treatment of a subject which kit comprises
in a first container a composition comprising delivery vehicles stably associated with at least one first therapeutic agent;
in a second container a second composition comprising delivery vehicles stably associated with at least a second therapeutic agent;
wherein the delivery vehicles in said first and second compositions are coordinated with respect to pharmacokinetic behavior; and
wherein said kit further contains instructions for administering said first and second composition at ratios of said first and second therapeutic agent that are non-antagonistic and/or wherein the amounts of said first and second compositions in said containers is proportional to a ratio of said first and second therapeutic agent that is non-antagonistic and/or said containers are calibrated to dispense amounts of said first and second composition wherein the ratio of first and second therapeutic agents is non-antagonistic.

### Claim 55 (depends on 54)

The kit of claim 54, wherein the containers are syringes.
